Phase 2 Trial Of CP-751,871 And Docetaxel In Advanced Breast Cancer

Inclusion Criteria: * histologically or cytologically confirmed diagnosis with evidence of either metastatic disease (Stage IV) of locally recurrent disease not amenable to curative resection or radiation therapy (Stage IIIB). * Her-2negative breast cancer or unknown Her-2 status. * at least 1 measurable lesion as defined by RECIST. * ECOG status 0-1 * adequate bone marrow, hepatic and renal function. * left ventricular ejection fraction of greater than or equal to 50%. * willingness to discontinue hormonal therapy. Exclusion Criteria: * any previous chemotherapy for advanced disease. * prior exposure to taxanes as (neo) adjuvant treatment less than 12 months prior to randomization. * symptomatic brain metastases. * prior anti-IGF-1R based investigational therapy. * peripheral neuropathy greater than grade 2.